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Tactical operators, inclusive of soldiers in the military, are reliant
upon their physiological and psychological state in often volatile and ex-
treme life or death situations that require correct decisions and precise
actions to ensure operational success with minimal collateral damage.
Accordingly, the development of physical andmental resilience are hall-
marks of prophylactic and remedial programs designed to ensure mili-
tary personnel are combat ready, thus optimising their capacity to
perform at expert levels, while reducing their risk of injury or the sever-
ity of injury sustained. Unfortunately, despite best efforts, current prac-
tices have not overcome the significant logistical challenges confronting
a military service member's routine exposure to moderate and severe
energy deficits upon deployment, resulting from unyielding energy de-
mands and restricted energy intake during missions [1]. Consequently,
these episodes of semi-starvation under complex and extreme tactical
environments produces a cascade of interlinked negative outcomes, in-
cluding a hypogonadal endocrine state (suppressed testosterone pro-
duction), loss of muscle-bone mass and strength, reduced functional
capacity, compromised cognition, and a suppressed immune system,
culminating in greater susceptibility to injury, illness and sub-optimal
performance, jeopardising their own welfare and the welfare of their
comrades.
Normal physiologic levels of serum testosterone expressed in
young men in the United States ranges from 10.4 to 34.7 nmol/L
(300 to 1000 ng/dL) [2]. However, military personnel express up to
65% less serum testosterone as a consequence of stress and duress ap-
plied in military training [3], reflecting the inevitable response also ex-
perienced by deployed military soldiers. To remedy hypogonadal
states induced by moderate-to-severe energy deficits and extreme op-
erational conditions, exogenous testosterone supplementation (testos-
terone replacement therapy) is a viable countermeasure to effectively
reverse the cascade of physical and mental consequences experienced
by tactical operators [4]. In alignment with clinical treatment of men
with chronically low testosterone levels, the updated Endocrine Society
clinical practice guidelines recommend a wide array of pharmacother-
apies, the most prominent of which is testosterone enanthate; an eas-
ily administered synthetic derivative of testosterone through
intramuscular injection; to be given at a starting rate of 75–100 mg/-
week on average [2]. Such strategies in the hypogonadal civilian have
been shown to produce predictable yet important benefits, such as in-
creased myogenesis and osteogenesis (muscle-bone mass and
strength), improved physical function, reduced anxiety, increased
mood, and increased cognition (i.e. attention, visual scanning ability,
executive function and psychomotor speed) [5,6]. These qualities are
critical to the performance of military personnel, though whether tes-
tosterone replacement produces equivalent outcomes under
moderate-to-severe energy deficits as a consequence of extreme oper-
ational conditions has yet to be clarified.
In EBioMedicine, Pasiakos and colleagues [1] report their initial re-
sults from an impressive three-phase, proof-of-concept, randomised,
double-blind, placebo-controlled trial; the first known rigorously con-
trolled study exploring this critical research question. We commend
the Military Nutrition Division of the US Army Research Institute of En-
vironmental Medicine and the Pennington Biomedical Research Center
for their ambitious undertaking to pursue this line of inquiry. Using a
14-day eucaloric control period, 28-day intervention of 200 mg/week
testosterone enanthate supplementation with an exercise- and diet-
induced energy deficit, and subsequent 14-day ad-libitum recovery
period; this study demonstrated a reduction in weight loss and
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improvement in lean mass gain, producing benefits in body composi-
tion and health status. However, the enduring effect of testosterone
enanthate has yet to be realised in their cohort, owing to the short-
term nature and time-points utilised, which may partly explain the
limited bandwidth of positive benefits described. For example,
strength benefits when supplementing with testosterone enanthate
are typically observed after 6 weeks of administration [7] with ergo-
genic muscle mass increases preceding strength benefits. This may
partly explain the observed increase in muscle mass but not strength
in Pasiakos and colleagues [1], assessed after only 28 days of treatment.
In addition, the single-joint isokinetic muscle function test used in
their trial is limited by mechanical specificity relative to training and
operations of military personnel, thus may lack sensitivity. The absence
of muscle function improvement in their trial must be considered in
this context.
Replica trials utilising longer-term interventions with longer-term
follow-up would be the next logical step to interrogate the therapeutic
utility of this treatment method for this population. This is vital as the
anabolic effects of testosterone replacement therapy inmilitary person-
nel has long-term implications [8], including protective effects on mus-
cle and bone (which may prevent stress fractures or load carriage
incidents [5]), and the likely improvement in recovery from completed
missions or injuries sustained. Most critical to the future of this work is
the evident generation and accumulation of myonuclei during hyper-
trophy [8], as myonuclei do not experience apoptosis during atrophy
or programmed cell death, thus new muscle mass developed during
youth and through ergogenic means provides lasting physiological ben-
efits that facilitates faster re-growth of lost muscle [9], faster re-gain of
lostmuscle strength, and faster recovery in unavoidable caseswhere at-
rophy has to occur. This also has considerable potential to delay the
onset of sarcopenia and osteoporosis later in life; a downstream benefit
worthy of exploration. Lastly, controversy surrounding the use of exog-
enous testosterone and aggressive prostate cancer risk in older age re-
mains unresolved, as prostate cancer is known to thrive in
testosterone rich environments. Fortunately, this does not appear to
be supported in the literature, with increased exogenous or endogenous
testosterone levels in young men not associated with increased risk of
prostate cancer, increased prostate-specific antigen (PSA) levels or in-
creased prostate cancer aggressiveness at diagnosis [10], which would
otherwise present an ethical dilemma to this treatment pathway inmil-
itary personnel.
Longer-term companion and observational studies are advised to di-
rectly examinemany of the implicated and associated benefits and risks
for male military personnel over the mid-to-long term. Furthermore,
with the increased recruitment and integration of female personnel in
to military combat positions, studies evaluating the female endocrine
response to severe stress and its consequences are also needed.
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